Literature DB >> 21719449

Can emerging biomarkers of myocardial remodelling identify asymptomatic hypertensive patients at risk for diastolic dysfunction and diastolic heart failure?

Patrick Collier1, Chris J Watson, Victor Voon, Dermot Phelan, Aftab Jan, George Mak, Ramon Martos, John A Baugh, Mark T Ledwidge, Kenneth M McDonald.   

Abstract

AIMS: Hypertension is one of the main drivers of the heart failure (HF) epidemic. The aims of this study were to profile fibro-inflammatory biomarkers across stages of the hypertensive heart disease (HHD) spectrum and to examine whether particular biochemical profiles in asymptomatic patients identify a higher risk of evolution to HF. METHODS AND
RESULTS: This was a cross-sectional observational study involving a population of 275 stable hypertensive patients divided into two different cohorts: Group 1, asymptomatic hypertension (AH) (n= 94); Group 2, HF with preserved ejection fraction  (n= 181). Asymptomatic hypertension patients were further subdivided according to left atrial volume index ≥34 mL/m(2) (n= 30) and <34 mL/m(2) (n= 64). Study assays involved inflammatory markers [interleukin 6 (IL6), interleukin 8 (IL8), monocyte chemoattractant protein 1 (MCP1), and tumour necrosis factor α], collagen 1 and 3 metabolic markers [carboxy-terminal propeptide of collagen 1, amino-terminal propeptide of collagen 1, amino-terminal propeptide of collagen 3 (PIIINP), and carboxy-terminal telopeptide of collagen 1 (CITP)], extra-cellular matrix turnover markers [matrix metalloproteinase 2 (MMP2), matrix metalloproteinase 9 (MMP9), and tissue inhibitor of metalloproteinase 1 (TIMP1)], and the brain natriuretic peptide. Data were adjusted for age, sex, systolic blood pressure, and creatinine. Heart failure with preserved ejection fraction  was associated with an increased inflammatory signal (IL6, IL8, and MCP1), an increased fibrotic signal (PIIINP and CITP), and an increased matrix turnover signal (MMP2 and MMP9). Alterations in MMP and TIMP enzymes were found to be significant indicators of greater degrees of asymptomatic left ventricular diastolic dysfunction.
CONCLUSION: These data define varying fibro-inflammatory profiles throughout different stages of HHD. In particular, the observations on MMP9 and TIMP1 raise the possibility of earlier detection of those at risk of evolution to HF which may help focus effective preventative strategies.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21719449     DOI: 10.1093/eurjhf/hfr079

Source DB:  PubMed          Journal:  Eur J Heart Fail        ISSN: 1388-9842            Impact factor:   15.534


  68 in total

Review 1.  Heart failure with preserved ejection fraction: mechanisms, clinical features, and therapies.

Authors:  Kavita Sharma; David A Kass
Journal:  Circ Res       Date:  2014-06-20       Impact factor: 17.367

Review 2.  Circulating biomarkers in patients with heart failure and preserved ejection fraction.

Authors:  Eileen O'Meara; Simon de Denus; Jean-Lucien Rouleau; Akshay Desai
Journal:  Curr Heart Fail Rep       Date:  2013-12

Review 3.  Emerging risk biomarkers in cardiovascular diseases and disorders.

Authors:  Ravi Kant Upadhyay
Journal:  J Lipids       Date:  2015-04-08

4.  Biological variation of extracellular matrix biomarkers in patients with stable chronic heart failure.

Authors:  Tobias Täger; Clara Wiebalck; Hanna Fröhlich; Anna Corletto; Hugo A Katus; Lutz Frankenstein
Journal:  Clin Res Cardiol       Date:  2017-08-04       Impact factor: 5.460

Review 5.  Management of Heart Failure with Preserved Ejection Fraction: Current Challenges and Future Directions.

Authors:  Bharathi Upadhya; Dalane W Kitzman
Journal:  Am J Cardiovasc Drugs       Date:  2017-08       Impact factor: 3.571

6.  Effect of Serum Albumin Levels in Patients With Heart Failure With Preserved Ejection Fraction (from the TOPCAT Trial).

Authors:  Stuart B Prenner; Anupam Kumar; Lei Zhao; Mary E Cvijic; Michael Basso; Thomas Spires; Zhuyin Li; Melissa Yarde; Priyanka Bhattacharya; Payman Zamani; Jeremy Mazurek; Zhaoqing Wang; Dietmar Seiffert; David A Gordon; Julio A Chirinos
Journal:  Am J Cardiol       Date:  2019-11-19       Impact factor: 2.778

Review 7.  Heart failure with preserved ejection fraction: molecular pathways of the aging myocardium.

Authors:  Francesco S Loffredo; Andriana P Nikolova; James R Pancoast; Richard T Lee
Journal:  Circ Res       Date:  2014-06-20       Impact factor: 17.367

Review 8.  Macrophages in Heart Failure with Reduced versus Preserved Ejection Fraction.

Authors:  Matthew DeBerge; Sanjiv J Shah; Lisa Wilsbacher; Edward B Thorp
Journal:  Trends Mol Med       Date:  2019-02-05       Impact factor: 11.951

Review 9.  Heart failure with preserved ejection fraction: emerging drug strategies.

Authors:  Fouad A Zouein; Lisandra E de Castro Brás; Danielle V da Costa; Merry L Lindsey; Mazen Kurdi; George W Booz
Journal:  J Cardiovasc Pharmacol       Date:  2013-07       Impact factor: 3.105

Review 10.  Aldosterone and cardiovascular disease: the heart of the matter.

Authors:  B Julie He; Mark E Anderson
Journal:  Trends Endocrinol Metab       Date:  2012-10-03       Impact factor: 12.015

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.